secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000886163-24-000026
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand acquires royalty rights on six partnered oncology programs and BOT/BAL from Agenus for $75M
--------------------------------------------------------------------------------

- Purchase price of $75M for 18.75% of licensed royalties and 31.875% of milestones on six partnered oncology programs (BMS, Gilead, Incyte, Merck, UroGen).
- Plus synthetic 2.625% royalty on future global net sales of Agenus' botensilimab/balstilimab (BOT/BAL) program.
- Ligand has option to commit additional $25M on pro rata basis; Sellers may raise up to $125M more total.
- Agenus issued Ligand warrant to purchase 867,052 shares of AGEN common stock at $17.30, exercisable until May 2029.
- Transaction expected to close in May 2024 subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000026/0000886163-24-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000026/lgnd-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer